• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Techcouver.com

 
 
  • News
  • Interviews
  • Thought Leadership
  • Bulletin Board
  • Job Board
  • About
    • Contact Us
  • Advertise

LightIntegra Raises $6.9 Million for Blood Analyzer Tech

April 25, 2019 by Techcouver Newsdesk Leave a Comment

Vancouver’s LightIntegra Technology has raised a $6.9 million Series A round led by Genome BC and Boardwalk Ventures and including Tower Beach Capital, Coleco Investments, and Quimby Investments. The company intends to use funding to bring its test to the US market.

LightIntegra has advanced ThromboLUX, a non-invasive, five-minute, easy-to-use optical test that assesses platelet activation status, which does not require dilution.

Failed platelet transfusions are a major issue in healthcare, critically impacting the care of blood cancer patients, and wasting $1.6 billion annually in the US. LightIntegra knows how painful failed transfusions are for physicians, the blood bank, and most importantly, the patients.

As a routine test for platelet concentrates, ThromboLUX identifies which platelet units may be best suited for prophylaxis and which units may be best suited for therapeutic use.

LightIntegra Technology launched from the Canadian Blood Services R&D labs through the efforts of research scientist Dr. Elisabeth Maurer and is currently led by CEO Bill Dubiel.

Filed Under: News Tagged With: LightIntegra

 
 

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

 
 

Stay Connected

  • Facebook
  • Instagram
  • LinkedIn
  • RSS
  • Twitter

About Us

Techcouver provides real-time reporting and analysis of emerging technology news in Vancouver and throughout British Columbia. The … READ MORE... about About Us

Copyright © 2023 Incubate Ventures

Privacy Policy